CN110650749A - 使用可溶性cd24进行神经保护和髓鞘再生的方法 - Google Patents

使用可溶性cd24进行神经保护和髓鞘再生的方法 Download PDF

Info

Publication number
CN110650749A
CN110650749A CN201880030068.0A CN201880030068A CN110650749A CN 110650749 A CN110650749 A CN 110650749A CN 201880030068 A CN201880030068 A CN 201880030068A CN 110650749 A CN110650749 A CN 110650749A
Authority
CN
China
Prior art keywords
protein
hours
ser
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880030068.0A
Other languages
English (en)
Chinese (zh)
Inventor
Y.刘
P.郑
N.李
M.德文波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens National Medical Center Inc
Oncolmmune Inc
Original Assignee
Childrens National Medical Center Inc
Oncolmmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens National Medical Center Inc, Oncolmmune Inc filed Critical Childrens National Medical Center Inc
Publication of CN110650749A publication Critical patent/CN110650749A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/528—CH4 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201880030068.0A 2017-05-15 2018-05-15 使用可溶性cd24进行神经保护和髓鞘再生的方法 Pending CN110650749A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506135P 2017-05-15 2017-05-15
US62/506,135 2017-05-15
PCT/US2018/032699 WO2018213266A1 (en) 2017-05-15 2018-05-15 Methods of use of soluble cd24 for neuroprotection and remyelination

Publications (1)

Publication Number Publication Date
CN110650749A true CN110650749A (zh) 2020-01-03

Family

ID=64274583

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880030068.0A Pending CN110650749A (zh) 2017-05-15 2018-05-15 使用可溶性cd24进行神经保护和髓鞘再生的方法

Country Status (8)

Country Link
US (2) US20200181235A1 (https=)
EP (1) EP3624838B1 (https=)
JP (1) JP2020519627A (https=)
KR (1) KR20200034957A (https=)
CN (1) CN110650749A (https=)
CA (1) CA3063894A1 (https=)
TW (1) TW201900671A (https=)
WO (1) WO2018213266A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160170A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231464A1 (en) 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
WO2020084034A1 (en) 2018-10-26 2020-04-30 F. Hoffmann-La Roche Ag Multispecific antibody screening method using recombinase mediated cassette exchange

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294884A1 (en) * 2000-03-29 2012-11-22 Yang Liu Methods of blocking tissue destruction by autoreactive t cells
CN104870014A (zh) * 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
US20150239953A1 (en) * 2010-04-28 2015-08-27 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US10689447B2 (en) * 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120294884A1 (en) * 2000-03-29 2012-11-22 Yang Liu Methods of blocking tissue destruction by autoreactive t cells
US20150239953A1 (en) * 2010-04-28 2015-08-27 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN104870014A (zh) * 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DENDROU等: "Immunopathology of multiple sclerosis" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021160170A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection

Also Published As

Publication number Publication date
TW201900671A (zh) 2019-01-01
EP3624838A4 (en) 2021-02-24
US20220098278A1 (en) 2022-03-31
JP2020519627A (ja) 2020-07-02
KR20200034957A (ko) 2020-04-01
CA3063894A1 (en) 2018-11-22
WO2018213266A1 (en) 2018-11-22
US20200181235A1 (en) 2020-06-11
EP3624838A1 (en) 2020-03-25
EP3624838B1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
ES2341842T3 (es) Bloqueo del crecimiento axonal mediado por el receptor de nogo.
JP5738333B2 (ja) 自己免疫疾患の治療及び診断のためのｔｃｒ−ｖベータ関連ペプチド
CN107531772B (zh) Cd24用于降低低密度脂蛋白胆固醇水平的用途
WO2009121176A1 (en) Insulin-induced gene (insig) peptide compositions and methods for cytoprotection
US20150044245A1 (en) Partial mhc constructs and methods of use
US20220098278A1 (en) Methods of Use of Soluble CD24 for Neuroprotection and Remyelination
EA039554B1 (ru) Способ снижения уровней a40 и/или a42 в нервной клетке и/или во внеклеточной жидкости
CN103339149B (zh) SorLA和GDNF-家族配体受体之间的相互作用的调节
CA2802207C (en) Materials and method for suppressing inflammatory and neuropathic pain
US10316075B2 (en) Recombinant polypeptides comprising MHC class II α1 domains
CA2520029C (en) Slurp-1 compositions and methods of use thereof
US20090214519A1 (en) Compositions and Methods for Treating Inflammation
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
JP7511551B2 (ja) 改変されたＭＨＣクラスＩＩ ＤＲα１ドメインを含む組換えポリペプチドおよび使用方法
EP1918299A1 (en) Modulators of cell adhesion molecules and use thereof
US11673916B2 (en) Neuroprotective peptides and methods of their use
CA3128503A1 (en) Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes
WO2002020047A9 (en) Chlamydial peptides and their mimics in demyelinating disease
CN110914286A (zh) 自噬抑制剂
WO2015168786A1 (en) Method for decreasing retinal ganglion cells degeneration

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200103